[1] Sun H, Saeedi P, Karuranga S, et al.IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119.
[2] Ruiz-ortega M, Rodrigues-diez RR, Lavoz C, et al. Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”[J]. J Clin Med, 2020, 9(3): 813.
[3] Gbd Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395(10225): 709-733.
[4] Almatroodi SA, Alnuqaydan AM, Babiker AY, et al.6-Gingerol, a Bioactive Compound of Ginger Attenuates Renal Damage in Streptozotocin-Induced Diabetic Rats by Regulating the Oxidative Stress and Inflammation[J]. Pharmaceutics, 2021, 13(3): 317.
[5] Saisho Y.SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?[J]. Diseases, 2020, 8(2): 14.
[6] Hopf M, Kloos C, Wolf G, et al.Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2[J]. J Clin Med, 2021, 10(4): 571.
[7] Asahara SI, Ogawa W.SGLT2 inhibitors and protection against pancreatic beta cell failure[J]. Diabetol Int, 2018, 10(1): 1-2.
[8] Cherney DZI, Zinman B, Inzucchi SE, et al.Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2017, 5(8): 610-621.
[9] Carbone S, Dixon DL.The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus[J]. Cardiovasc Diabetol, 2019, 18(1): 64.
[10] Mosenzon O, Wiviott SD, Cahn A, et al.Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial[J]. Lancet Diabetes Endocrinol, 2019, 7(8): 606-617.
[11] Perkovic V, Jardine MJ, Neal B, et al.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380(24): 2295-2306.
[12] Solomon SD, Mcmurray JJV, Claggett B, et al.Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction[J]. N Engl J Med, 2022, 387(12): 1089-1098.
[13] Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease[J]. Kidney Int, 2022, 102(5S): S1-S127.
[14] Ott C, Jung S, Korn M, et al.Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/ linagliptin with metformin/insulin glargine[J]. Cardiovasc Diabetol, 2021, 20(1): 178.
[15] Hirai T, Kitada M, Monno I, et al.Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice[J]. J Diabetes Investig, 2021, 12(9): 1577-1585.
[16] Park G, Choi B, Kang S, et al.Sodium-Glucose Cotransporter-2 Inhibitors Could Help Delay Renal Impairment in Patients with Type 2 Diabetes: A Real-World Clinical Setting[J]. J Clin Med, 2022, 11(18): 5259.
[17] Matsuba I, Kawata T, Iemitsu K, et al.Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study[J]. J Diabetes Investig, 2020, 11(5): 1248-1257.
[18] Jongs N, Greene T, Chertow GM, et al.Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD Trial[J]. Lancet Diabetes Endocrinol, 2021, 9(11): 755-766.
[19] Oshima M, Neuen BL, Li J, et al.Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial[J]. J Am Soc Nephrol, 2020, 31(12): 2925-2936.
[20] Hodrea J, Balogh DB, Hosszu A, et al.Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney[J]. Am J Physiol Renal Physiol, 2020, 318(4): F1017-F1029.
[21] Wang XX, Levi J, Luo Y, et al.SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE[J]. J Biol Chem, 2017, 292(13): 5335-5348.
[22] Zhang Z, Ni L, Zhang L, et al.Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy[J]. Diabetes Metab Syndr Obes, 2021, 14: 227-240.
[23] Gholam MF, Liu LP, Searcy LA, et al.Dapagliflozin Treatment Augments Bioactive Phosphatidylethanolamine Concentrations in Kidney Cortex Membrane Fractions of Hypertensive Diabetic db/db Mice and Alters the Density of Lipid Rafts in Mouse Proximal Tubule Cells[J]. Int J Mol Sci, 2023, 24(2): 1408.
[24] Zhou Y, Tai S, Zhang N, et al.Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation[J]. Biomed Pharmacother, 2023, 165: 115213.
[25] van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial[J]. Kidney Int, 2020, 97(1):202-212.
[26] Takashima H, Yoshida Y, Nagura C, et al.Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial[J]. Diab Vasc Dis Res, 2018, 15(5): 469-472.
[27] Chino Y, Samukawa Y, Sakai S, et al.SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria[J]. Biopharm Drug Dispos, 2014, 35(7): 391-404.
[28] Zhao Y, Xu L, Tian D, et al.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials[J]. Diabetes Obes Metab, 2018, 20(2): 458-462.
[29] Tanaka M, Yamakage H, Inoue T, et al.Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial[J]. Intern Med, 2020, 59(5): 601-609.
[30] Xu J, Kitada M, Ogura Y, et al.Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells[J]. Cells, 2021, 10(6): 1457.
[31] Birnbaum Y, Chen H, Tran D, et al.Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus[J]. Cardiovasc Drugs Ther, 2022, 36(5): 829-840.
[32] Das NA, Carpenter AJ, Belenchia A, et al.Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition[J]. Cell Signal, 2020, 68: 109506.
[33] Lega IC, Bronskill SE, Campitelli MA, et al.Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes[J]. Diabetes Obes Metab, 2019, 21(11): 2394-2404.
[34] Toyama T, Neuen BL, Jun M, et al.Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis[J]. Diabetes Obes Metab, 2019, 21(5): 1237-1250.
[35] Herring RA, Shojaee-moradie F, Garesse R, et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes[J]. Diabetes Care, 2020, 43(9): 2128-2136.
[36] Tomita I, Kume S, Sugahara S, et al. SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition[J]. Cell Metab, 2020, 32(3): 404-419.e6.
[37] Blau JE, Tella SH, Taylor SI, et al.Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data[J]. Diabetes Metab Res Rev, 2017, 33(8): 10.
[38] Horii T, Oikawa Y, Atsuda K, et al.On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes[J]. J Diabetes Investig, 2021, 12(9): 1586-1593.
[39] Aloe S, Filliter C, Salmasi S, et al.Sodium-glucose cotransporter 2 inhibitors and the risk of venous thromboembolism: A population-based cohort study[J]. Br J Clin Pharmacol, 2023, 89(9): 2902-2914.
[40] Menne J, Dumann E, Haller H, et al.Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis[J]. PLoS Med, 2019, 16(12): e1002983. |
